Gene info: ID 5290

Gene: PIK3CA

GENE ID: 5290

Description: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

Gene type: protein-coding

Location: 3q26.32

dbXrefs: Ensembl:ENSG00000121879 MIM:171834 Vega:OTTHUMG00000157311 UniprotKB:P42336

RefSeq: NG_012113.2

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND|AD

# Publications: 63

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 8.057e-1 (AD) 5.350e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs17592582	chr3:179192562 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ZBTB38	0.926
APPBP2	0.9
PIKFYVE	0.898
KIAA1109	0.893
NCOA2	0.892
ZNF510	0.89
APPL1	0.89
RAB3GAP2	0.889
PPP1R12A	0.888
ARFGEF1	0.887

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.524
OR4F29	-0.476
S100A1	-0.305
NANOGNB	-0.296
SOX3	-0.286
RBP1	-0.282
BCL7C	-0.281
TNFRSF13B	-0.279
AQP5	-0.279
S100A14	-0.269

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00171	ATP	Small Molecule	56-65-5	Investigational\|Nutraceutical	Target
DB00201	Caffeine	Small Molecule	58-08-2	Approved	Target
DB05241	XL765	Small Molecule	-	Investigational	Target
DB08059	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE	Small Molecule		Experimental	Target
DB11772	Pilaralisib	Small Molecule	934526-89-3	Investigational	Target
DB12483	Copanlisib	Small Molecule	1032568-63-0	Approved\|Investigational	Target

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004674	protein serine/threonine kinase activity	-	IEA	-
GO:0005515	protein binding	-	IPI	10490823 16043515 16150444 17475214 19411071 19574958 19805105 20018188 20713702 22402981 23643389 23676467 24189400 25253337 25814554 26496610
GO:0005524	ATP binding	-	IEA	-
GO:0016301	kinase activity	-	IDA	25327288
GO:0016301	kinase activity	-	TAS	-
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	IBA	21873635
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	IDA	2174051
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	TAS	-
GO:0030295	protein kinase activator activity	-	IEA	-
GO:0035004	phosphatidylinositol 3-kinase activity	-	ISS	-
GO:0035004	phosphatidylinositol 3-kinase activity	-	TAS	19200708
GO:0035005	1-phosphatidylinositol-4-phosphate 3-kinase activity	-	IBA	21873635
GO:0043560	insulin receptor substrate binding	-	IEA	-
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	IBA	21873635
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	TAS	-
GO:0052742	phosphatidylinositol kinase activity	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001525	angiogenesis	-	IEA	-
GO:0001889	liver development	-	IEA	-
GO:0001944	vasculature development	-	TAS	19200708
GO:0006006	glucose metabolic process	-	IEA	-
GO:0006468	protein phosphorylation	-	IBA	21873635
GO:0007173	epidermal growth factor receptor signaling pathway	-	TAS	-
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007411	axon guidance	-	TAS	-
GO:0010468	regulation of gene expression	-	IEA	-
GO:0014065	phosphatidylinositol 3-kinase signaling	-	IBA	21873635
GO:0016242	negative regulation of macroautophagy	-	NAS	23778976
GO:0016310	phosphorylation	-	IDA	25327288
GO:0016477	cell migration	-	IBA	21873635
GO:0019221	cytokine-mediated signaling pathway	-	TAS	-
GO:0030168	platelet activation	-	IBA	21873635
GO:0030168	platelet activation	-	TAS	21035500
GO:0031295	T cell costimulation	-	TAS	-
GO:0032008	positive regulation of TOR signaling	-	NAS	23778976
GO:0032147	activation of protein kinase activity	-	IEA	-
GO:0033138	positive regulation of peptidyl-serine phosphorylation	-	IEA	-
GO:0036092	phosphatidylinositol-3-phosphate biosynthetic process	-	IBA	21873635
GO:0036092	phosphatidylinositol-3-phosphate biosynthetic process	-	IEA	-
GO:0038028	insulin receptor signaling pathway via phosphatidylinositol 3-kinase	-	TAS	19200708
GO:0038095	Fc-epsilon receptor signaling pathway	-	TAS	-
GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	-	TAS	-
GO:0038128	ERBB2 signaling pathway	-	TAS	-
GO:0040014	regulation of multicellular organism growth	-	IEA	-
GO:0043276	anoikis	-	NAS	23778976
GO:0043457	regulation of cellular respiration	-	IEA	-
GO:0043491	protein kinase B signaling	-	IEA	-
GO:0043524	negative regulation of neuron apoptotic process	-	IEA	-
GO:0043542	endothelial cell migration	-	TAS	19200708
GO:0044029	hypomethylation of CpG island	-	IEA	-
GO:0046854	phosphatidylinositol phosphorylation	-	IBA	21873635
GO:0046854	phosphatidylinositol phosphorylation	-	ISS	-
GO:0048010	vascular endothelial growth factor receptor signaling pathway	-	TAS	-
GO:0048015	phosphatidylinositol-mediated signaling	-	IBA	21873635
GO:0048015	phosphatidylinositol-mediated signaling	-	TAS	-
GO:0050852	T cell receptor signaling pathway	-	TAS	-
GO:0050900	leukocyte migration	-	TAS	-
GO:0051897	positive regulation of protein kinase B signaling	-	TAS	-
GO:0060048	cardiac muscle contraction	-	TAS	19147653
GO:0060612	adipose tissue development	-	IEA	-
GO:0071333	cellular response to glucose stimulus	-	IEA	-
GO:0097009	energy homeostasis	-	IEA	-
GO:2000270	negative regulation of fibroblast apoptotic process	-	IEA	-
GO:2000653	regulation of genetic imprinting	-	IEA	-
GO:2000811	negative regulation of anoikis	-	IMP	22402981

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005942	phosphatidylinositol 3-kinase complex	-	IBA	21873635
GO:0005942	phosphatidylinositol 3-kinase complex	-	ISS	-
GO:0005943	phosphatidylinositol 3-kinase complex, class IA	-	IBA	21873635
GO:0005943	phosphatidylinositol 3-kinase complex, class IA	-	IDA	22402981
GO:0016020	membrane	-	IBA	21873635
GO:0030027	lamellipodium	-	IEA	-

KEGG ID	KEGG Term
hsa00562	Inositol phosphate metabolism
hsa04012	ErbB signaling pathway
hsa04062	Chemokine signaling pathway
hsa04070	Phosphatidylinositol signaling system
hsa04150	mTOR signaling pathway
hsa04210	Apoptosis
hsa04370	VEGF signaling pathway
hsa04380	Osteoclast differentiation
hsa04510	Focal adhesion
hsa04620	Toll-like receptor signaling pathway
hsa04630	Jak-STAT signaling pathway
hsa04650	Natural killer cell mediated cytotoxicity
hsa04660	T cell receptor signaling pathway
hsa04662	B cell receptor signaling pathway
hsa04664	Fc epsilon RI signaling pathway
hsa04666	Fc gamma R-mediated phagocytosis
hsa04670	Leukocyte transendothelial migration
hsa04722	Neurotrophin signaling pathway
hsa04810	Regulation of actin cytoskeleton
hsa04910	Insulin signaling pathway
hsa04914	Progesterone-mediated oocyte maturation
hsa04930	Type II diabetes mellitus
hsa04960	Aldosterone-regulated sodium reabsorption
hsa04973	Carbohydrate digestion and absorption
hsa05100	Bacterial invasion of epithelial cells
hsa05142	Chagas disease (American trypanosomiasis)
hsa05145	Toxoplasmosis
hsa05146	Amoebiasis
hsa05160	Hepatitis C
hsa05200	Pathways in cancer
hsa05210	Colorectal cancer
hsa05211	Renal cell carcinoma
hsa05212	Pancreatic cancer
hsa05213	Endometrial cancer
hsa05214	Glioma
hsa05215	Prostate cancer
hsa05218	Melanoma
hsa05220	Chronic myeloid leukemia
hsa05221	Acute myeloid leukemia
hsa05222	Small cell lung cancer
hsa05223	Non-small cell lung cancer

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-114604	GPVI-mediated activation cascade	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1227986	Signaling by ERBB2	TAS
R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	TAS
R-HSA-1236394	Signaling by ERBB4	TAS
R-HSA-1250342	PI3K events in ERBB4 signaling	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	IEA
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-1430728	Metabolism	TAS
R-HSA-1433557	Signaling by SCF-KIT	TAS
R-HSA-1483255	PI Metabolism	TAS
R-HSA-1483257	Phospholipid metabolism	TAS
R-HSA-1500931	Cell-Cell communication	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-1643685	Disease	TAS
R-HSA-1643713	Signaling by EGFR in Cancer	TAS
R-HSA-1660499	Synthesis of PIPs at the plasma membrane	TAS
R-HSA-166520	Signaling by NTRKs	IEA
R-HSA-166520	Signaling by NTRKs	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-168256	Immune System	IEA
R-HSA-177929	Signaling by EGFR	TAS
R-HSA-180292	GAB1 signalosome	TAS
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	TAS
R-HSA-1839124	FGFR1 mutant receptor activation	TAS
R-HSA-186763	Downstream signal transduction	TAS
R-HSA-186797	Signaling by PDGF	TAS
R-HSA-187037	Signaling by NTRK1 (TRKA)	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-194138	Signaling by VEGF	TAS
R-HSA-194138	Signaling by VEGF	IEA
R-HSA-1963642	PI3K events in ERBB2 signaling	TAS
R-HSA-198203	PI3K/AKT activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-202403	TCR signaling	TAS
R-HSA-202424	Downstream TCR signaling	TAS
R-HSA-202733	Cell surface interactions at the vascular wall	TAS
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	TAS
R-HSA-2029485	Role of phospholipids in phagocytosis	TAS
R-HSA-210993	Tie2 Signaling	TAS
R-HSA-2172127	DAP12 interactions	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2424491	DAP12 signaling	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	TAS
R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373753	Nephrin family interactions	IEA
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-388841	Costimulation by the CD28 family	TAS
R-HSA-389356	CD28 co-stimulation	TAS
R-HSA-389357	CD28 dependent PI3K/Akt signaling	TAS
R-HSA-392451	G beta:gamma signalling through PI3Kgamma	TAS
R-HSA-397795	G-protein beta:gamma signalling	TAS
R-HSA-416476	G alpha (q) signalling events	TAS
R-HSA-416482	G alpha (12/13) signalling events	TAS
R-HSA-422475	Axon guidance	TAS
R-HSA-4420097	VEGFA-VEGFR2 Pathway	TAS
R-HSA-4420097	VEGFA-VEGFR2 Pathway	IEA
R-HSA-449147	Signaling by Interleukins	IEA
R-HSA-449147	Signaling by Interleukins	TAS
R-HSA-451927	Interleukin-2 family signaling	TAS
R-HSA-512988	Interleukin-3, 5 and GM-CSF signaling	IEA
R-HSA-512988	Interleukin-3, 5 and GM-CSF signaling	TAS
R-HSA-556833	Metabolism of lipids	TAS
R-HSA-5637810	Constitutive Signaling by EGFRvIII	TAS
R-HSA-5637812	Signaling by EGFRvIII in Cancer	TAS
R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654689	PI-3K cascade:FGFR1	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654710	PI-3K cascade:FGFR3	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655291	Signaling by FGFR4 in disease	TAS
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-6806834	Signaling by MET	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-8851907	MET activates PI3K/AKT signaling	TAS
R-HSA-8853334	Signaling by FGFR3 fusions in cancer	TAS
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-8853659	RET signaling	TAS
R-HSA-9006115	Signaling by NTRK2 (TRKB)	IEA
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-9028335	Activated NTRK2 signals through PI3K	IEA
R-HSA-912526	Interleukin receptor SHC signaling	TAS
R-HSA-912631	Regulation of signaling by CBL	IEA
R-HSA-912631	Regulation of signaling by CBL	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24743704	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. (2014 May 27)	Li S	Br J Cancer
26208325	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)	Chatziandreou I	PLoS One
25745045	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May)	Couraud S	Eur Respir J
25366782	Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer. (2014 Oct 31)	Han Y	Genet Mol Res
22707299	Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)	Ren S	Cell Biochem Biophys
21507233	Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). (2011 Apr 20)	Ji M	BMC Cancer
24055406	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013 Nov)	Hosgood HD 3rd	Respir Med
26893860	Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)	Furukawa M	Mol Clin Oncol
25351745	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)	Arcila ME	Clin Cancer Res
28024696	PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. (2017 Jan)	McGowan M	Lung Cancer
18242762	EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. (2008 Aug)	Shinmura K	Lung Cancer
23877438	CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct)	Matsuura S	Oncol Rep
24828667	Small-cell lung cancers in patients who never smoked cigarettes. (2014 Jun)	Varghese AM	J Thorac Oncol
22430133	Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. (2011-2012)	Xu J	Cancer Biomark
28753770	Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. (2016 Jun 24)	Joshi M	Eur Urol Focus
27750372	Copy number gain of 11q13.3 genes associates with pathological stage in hypopharyngeal squamous cell carcinoma. (2017 Mar)	Pattle SB	Genes Chromosomes Cancer
14581353	Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15)	Miller CT	Clin Cancer Res
20507599	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. (2010 May 27)	Baba Y	Mol Cancer
26527886	SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. (2015)	Zheng S	Onco Targets Ther
26834999	Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence. (2015)	Krishnan N	F1000Res
26164066	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)	Preusser M	Eur J Cancer
25122428	Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. (2014 Sep)	Umemura S	J Thorac Oncol
16930767	PIK3CA mutation status in Japanese lung cancer patients. (2006 Nov)	Kawano O	Lung Cancer
25738220	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)	Sholl LM	J Thorac Oncol
26200269	Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)	Shim HS	J Thorac Oncol
25152623	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014)	Hu H	Onco Targets Ther
28625654	LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. (2017 Jun)	Imperatori A	Lung Cancer
28652248	GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. (2017 Aug 15)	Kasiri S	Cancer Res
25109408	Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. (2014 Oct)	Jiang N	Oncol Rep
26923333	Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. (2016 Feb 29)	Shi X	Sci Rep
23723294	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)	Dearden S	Ann Oncol
25234657	Tongue carcinoma infrequently harbor common actionable genetic alterations. (2014 Sep 19)	Tan DS	BMC Cancer
28840008	Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul)	Zhang J	J Thorac Dis
28881815	Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8)	Dugay F	Oncotarget
26900290	Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. (2016 Feb 21)	Sasaki Y	World J Gastroenterol
26873401	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May)	Sawada G	Gastroenterology
29650325	Improving the genetic signature of prostate cancer, the somatic mutations. (2018 Jun)	Martinez-Gonzalez LJ	Urol Oncol
23674897	PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. (2013)	Zhang L	Onco Targets Ther
25631445	Comprehensive genomic characterization of head and neck squamous cell carcinomas. (2015 Jan 29)	-	Nature
29246019	Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. (2017 Nov 21)	Liu R	Oncotarget
26423386	Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. (2015 Nov)	Lochhead P	Am J Clin Nutr
24729716	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)	Li H	Onco Targets Ther
28169993	The evolving genomic landscape of urothelial carcinoma. (2017 Feb 7)	Glaser AP	Nat Rev Urol
24736592	Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. (2014)	Toschi L	PLoS One
27033383	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)	Chen LF	Zhonghua Bing Li Xue Za Zhi
22768234	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)	An SJ	PLoS One
22975805	The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)	Seo JS	Genome Res
24910434	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. (2014 Jun 26)	Henderson S	Cell Rep
25839328	Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. (2015 Apr 2)	Zhang L	Am J Hum Genet
26851496	Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population. (2016 May)	Leduc N	J Thorac Oncol
23802852	Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)	McQuitty E	Arch Pathol Lab Med
26711930	Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. (2016 Jan)	Tissot C	Lung Cancer
24942490	ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. (2014 Nov)	Tuononen K	Genes Chromosomes Cancer
27565922	Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)	Maki-Nevala S	Lung Cancer
26860843	Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. (2016 Oct)	Nicos M	Clin Transl Oncol
25007143	Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)	Boland JM	Am J Surg Pathol
26801617	Obesity and colorectal cancer: molecular features of adipose tissue. (2016 Jan 22)	Martinez-Useros J	J Transl Med
21212151	Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. (2011 Apr)	Wu IC	Carcinogenesis
25488863	Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. (2015 Feb)	Qiong Z	Lung Cancer
24278325	Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. (2013)	Urashima M	PLoS One
25567908	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)	Drilon A	Clin Cancer Res
29191607	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. (2017 Oct)	Sawa K	Lung Cancer
23098378	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)	Li H	Lung Cancer

ID	Drug Name	Action	PubMed
C569670	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	"1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one results in decreased activity of PIK3CA protein"	21998291
C569670	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	"PIK3CA gene mutant form results in increased susceptibility to 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"	23136191
C569670	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	"[PTEN gene mutant form co-treated with PIK3CA gene mutant form] results in increased susceptibility to 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"	23136191
C569670	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	"1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one results in decreased activity of PIK3CA protein"	21981714
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine binds to and results in decreased activity of PIK3CA protein"	18754654
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]"	18754654
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased activity of PIK3CA protein mutant form"	18754654
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"ERBB2 gene mutant form promotes the reaction [PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"PIK3CA gene mutant form promotes the reaction [ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"PIK3CA gene mutant form promotes the reaction [PTEN gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"	20453058\|2313619
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ABCF2 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ABHD15 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ACOX2 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ADCY3 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ADRM1 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of AGO2 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of AMD1 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ANKRD52 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of ARPC5L mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of AUNIP mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of B3GALNT1 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of B4GALT2 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of BID mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of BOK mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of BOP1 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of C11ORF24 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of C3ORF70 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CACYBP mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CAPN15 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CARD10 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CARS mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CBX2 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCDC137 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCDC85B mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCDC86 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCND1 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCND1 protein"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCND3 mRNA"	20453058
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of CCNE2 mRNA"	20453058